Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | SLC9A3 | P48764 | 2/20 | 0.37 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.37 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.35 |
| ▸ | APEX1 | P27695 | 3/20 | 0.35 |
| ▸ | ERN1 | O75460 | 1/20 | 0.32 |
| ▸ | NOS2 | P35228 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3597473 | 0.75 | AKR1C3 (0.46) | KDM4EAKR1C3HDAC1APEX1ERN1 | |
| SCHEMBL3033598 | 0.72 | AKR1C3 (0.42) | KDM4ESLC9A3SLC9A1AKR1C3APEX1 | |
| SCHEMBL3033600 | 0.72 | AKR1C3 (0.42) | KDM4ESLC9A3SLC9A1AKR1C3APEX1 | |
| SCHEMBL544577 | 0.71 | ERN1 (0.42) | KDM4ESLC9A3SLC9A1AKR1C3APEX1 | |
| SCHEMBL544575 | 0.71 | ERN1 (0.42) | KDM4ESLC9A3SLC9A1AKR1C3APEX1 | |
| SCHEMBL20670887 | 0.70 | KDM4E (0.47) | KDM4EHDAC1HDAC6 | |
| SCHEMBL6120291 | 0.70 | KDM4E (0.68) | KDM4EHDAC1HDAC6 | |
| SCHEMBL7094608 | 0.69 | CES2 (0.42) | AKR1C3APEX1ERN1 | |
| SCHEMBL14319659 | 0.69 | SLC9A3 (0.47) | KDM4ESLC9A3SLC9A1AKR1C3APEX1 | |
| SCHEMBL7094606 | 0.69 | CES2 (0.42) | AKR1C3APEX1ERN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7709491-B2 | Substituted quinazolines as antiviral agents, especially against cytomegaloviruses | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-05-04 | — | — | US | disclosed |
| US-20060235032-A1 | Substituted quinazolines as antiviral agents, especially against cytomegaloviruses | AIC246 AG & CO. KG (DE) | 2006-10-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060235032-A1 | Substituted quinazolines as antiviral agents, especially against cytomegaloviruses | TPMT, EIF2AK2, IRF3 | KDM4E 1877/4885SLC9A3 3547/4885SLC9A1 4279/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.